Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Dr. Jayne S. Gurtler

Hematology Oncology | Hematology | Oncology
Crescent City Physicians Inc
100 W Harrison Ave, Suite 101, 
New Orleans, LA 
Accepting New Patients
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Crescent City Physicians Inc
100 W Harrison Ave, Suite 101, 
New Orleans, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jayne Gurtler is a Hematologist Oncology specialist and a Hematologist in New Orleans, Louisiana. Dr. Gurtler is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Paget Disease of the Breast, Lung Cancer, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma. Dr. Gurtler is currently accepting new patients.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in LA
Hospital Affiliations
East Jefferson General Hospital
West Jefferson Medical Center
Touro Infirmary
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

CRESCENT CITY PHYSICIANS INC
100 W Harrison Ave, Suite 101, New Orleans, LA 70124
Other Locations
CRESCENT CITY PHYSICIANS INC
2121 Ridgelake Dr, Metairie, LA 70001
CRESCENT CITY PHYSICIANS INC
2820 Canal St, New Orleans, LA 70119

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 27, 2020
Intervention Type: Biological
Study Phase: Phase 1
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: September 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

6 Total Publications

Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization.
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization.
Journal: The oncologist
Published: July 26, 2022
Similar Doctors
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Sumathi S. Smith
Hematology Oncology | Hematology | Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Sumathi S. Smith
Hematology Oncology | Hematology | Oncology

Ochsner Clinic LLC

1001 Gause Blvd, 
Slidell, LA 
 (28.2 miles away)
985-646-5970
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sumathi Smith is a Hematologist Oncology specialist and a Hematologist in Slidell, Louisiana. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Lung Cancer. Dr. Smith is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Burke J. Brooks
Hematology Oncology | Hematology | Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Burke J. Brooks
Hematology Oncology | Hematology | Oncology

Ochsner Clinic LLC

104 Acadia Park Dr, 
Raceland, LA 
 (34.1 miles away)
985-537-3211
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Burke Brooks is a Hematologist Oncology specialist and a Hematologist in Raceland, Louisiana. Dr. Brooks is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Multiple Myeloma, and Autoimmune Hemolytic Anemia. Dr. Brooks is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Sukanthini Subbiah
Hematology Oncology | Hematology | Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Sukanthini Subbiah
Hematology Oncology | Hematology | Oncology

Ochsner Clinic LLC

1514 Jefferson Hwy, 
New Orleans, LA 
 (3.5 miles away)
504-842-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sukanthini Subbiah is a Hematologist Oncology specialist and a Hematologist in New Orleans, Louisiana. Dr. Subbiah is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome. Dr. Subbiah is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gurtler's expertise for a condition
ConditionClose
    View All 29 Advanced Conditions
    View All 115 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile